Phase 1 study of DS-3201b to assess the effects of itraconazole and fluconazole on the pharmacokinetics of single oral administration of DS-3201b tablets in healthy Japanese subjects

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223846

Enrollment

Registered

2018-03-19

Start date

2018-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

investigational material(s) Generic name etc : DS-3201b INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Japanese males 2.Age: >=20 and ==18.5 and <25.0 (at screening)

Exclusion criteria

Exclusion criteria: 1.Having a history of hypersensitivity to drugs or other substances or being idiosyncratic (eg, having penicillin allergy) 2.Having alcohol or drug dependence

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

Daiichi Sankyo Co., Ltd.

+81-3-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026